How Analysts Feel About Spark Therapeutics, Inc. (NASDAQ:ONCE)?

September 16, 2018 - By Theresa Judd

Spark Therapeutics, Inc. (NASDAQ:ONCE) LogoInvestors sentiment is 1.19 in 2018 Q2. Its the same as in 2018Q1. It is the same, as 17 investors sold Spark Therapeutics, Inc. shares while 46 reduced holdings. only 24 funds opened positions while 51 raised stakes. 37.08 million shares or 0.93% more from 36.74 million shares in 2018Q1 were reported.
38,396 are held by Mutual Of America Cap Mgmt Ltd Liability. D E Shaw Co Inc, a New York-based fund reported 507,656 shares. 11,511 were reported by Partner Investment Mgmt Lp. Pnc Financial Services Group holds 2,600 shares or 0% of its portfolio. Tci Wealth Advsr reported 6 shares stake. Employees Retirement Association Of Colorado has 0% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 3,179 shares. Blackrock has invested 0.01% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Millennium Lc invested in 0.01% or 101,133 shares. Rhenman And Prtn Asset Mngmt Ab reported 1.5% stake. Fincl Architects Inc has 170 shares. Columbia Prtn L L C Investment holds 0.36% in Spark Therapeutics, Inc. (NASDAQ:ONCE) or 15,074 shares. 165,264 were accumulated by Schwab Charles Inv Mngmt. The Nebraska-based Cwm Limited Liability Corporation has invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Winslow Evans Crocker invested in 0% or 60 shares. Fil Limited reported 76,217 shares.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Coverage

Among 14 analysts covering Spark Therapeutics (NASDAQ:ONCE), 5 have Buy rating, 1 Sell and 8 Hold. Therefore 36% are positive. Spark Therapeutics had 21 analyst reports since March 29, 2018 according to SRatingsIntel. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) earned “Buy” rating by Cantor Fitzgerald on Monday, April 30. The rating was maintained by Barclays Capital with “Overweight” on Wednesday, August 8. The firm earned “Buy” rating on Thursday, March 29 by Mizuho. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) earned “Outperform” rating by BMO Capital Markets on Wednesday, May 9. UBS maintained the shares of ONCE in report on Wednesday, August 8 with “Neutral” rating. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, May 9. The company was maintained on Tuesday, May 8 by Cantor Fitzgerald. On Monday, April 23 the stock rating was downgraded by Chardan Capital Markets to “Neutral”. The company was maintained on Wednesday, August 8 by Stifel Nicolaus. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) earned “Hold” rating by Leerink Swann on Monday, May 7. Below is a list of Spark Therapeutics, Inc. (NASDAQ:ONCE) latest ratings and price target changes.

08/08/2018 Broker: UBS Old Rating: Neutral New Rating: Neutral Old Target: $80 New Target: $53 Maintain
08/08/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $85 New Target: $77 Maintain
08/08/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Market Perform Old Target: $98 Downgrade
08/08/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $76 New Target: $68 Maintain
07/08/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Underperform Old Target: $98 Downgrade
19/07/2018 Broker: RBC Capital Markets Old Rating: Outperform New Rating: Sector Perform Old Target: $100 Downgrade
09/07/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $75 New Target: $98 Maintain
28/06/2018 Broker: FBR Capital Rating: Neutral New Target: $74 Initiates Coverage On
25/06/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $78 New Target: $98 Maintain
22/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $103.0000 Maintain

The stock decreased 0.15% or $0.09 during the last trading session, reaching $58.95. About 440,462 shares traded. Spark Therapeutics, Inc. (NASDAQ:ONCE) has declined 28.27% since September 16, 2017 and is downtrending. It has underperformed by 43.89% the S&P500.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company has market cap of $2.22 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It currently has negative earnings. The companyÂ’s products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

More recent Spark Therapeutics, Inc. (NASDAQ:ONCE) news were published by: Nasdaq.com which released: “Is Spark Therapeutics a Bad News Buy?” on August 18, 2018. Also Globenewswire.com published the news titled: “Report: Exploring Fundamental Drivers Behind Fiesta Restaurant Group, Emerge Energy Services LP, Collegium …” on August 24, 2018. Seekingalpha.com‘s news article titled: “Sangamo (Part V): Assessing The Prospects Of SB-913” with publication date: September 11, 2018 was also an interesting one.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.